Anticancer Drugs in End‐Stage Kidney Disease Patients
- 11 April 2015
- journal article
- Published by Wiley in Seminars in Dialysis
- Vol. 28 (4) , 413-416
Abstract
The increased incidence of malignancies in patients with chronic kidney patients and especially in end‐stage kidney disease (ESKD) patients has been discussed since the mid‐1970s. Consequently, oncologists, nephrologists, and pharmacists are increasingly facing challenging situations of cytotoxic drug handling in dialysis patients because of pharmacokinetic modifications. In these patients, two main issues must be considered. First, the absence of renal function in hemodialysis (HD) patients may necessitate drug dosage reduction. Therefore, drug prescription must be cautiously checked before administration with appropriate dosage adjustment whenever necessary to ensure efficacy while avoiding overdosage and related side effects. Second, drug clearance by dialysis session must be taken into account for appropriate chemotherapy timing administration to avoid drug removal, which may result in a loss of efficacy. These two main considerations must not be considered as a contra‐indication to chemotherapy in ESKD patients, but more as a need for an individualized prescription according to available recommendations.Keywords
This publication has 28 references indexed in Scilit:
- Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) studyAnnals of Oncology, 2012
- Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic ImpairmentClinical Pharmacokinetics, 2010
- Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal FunctionThe Journal of Clinical Pharmacology, 2010
- Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patientsAnnals of Oncology, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- Renal Tubular Drug TransportersNephron Physiology, 2006
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Principles of Drug Administration in Renal InsufficiencyClinical Pharmacokinetics, 1997
- Malignant Tumors in Hemodialysis PatientsNephron, 1996
- Increased Incidence of Malignancy in Chronic Renal FailureNephron, 1977